Navigation Links
Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
Date:3/24/2009

ing a MACE rate of 3.6 percent (one patient) at two years. MACE is a composite clinical measure of safety and efficacy outcomes, defined as any event that resulted in re-treatment of the treated artery lesion (ischemia-driven target lesion revascularization), heart attack (myocardial infarction) or cardiac death.

"Based on the strong clinical outcomes from the first stage of Abbott's bioabsorbable device trial, interventional cardiologists have been eager to enroll their patients into the second stage of the trial," said John Ormiston, M.D., medical director at Mercy Hospital in Auckland, New Zealand, and co-principal investigator in the ABSORB trial. "If the bioabsorbable stent continues to perform well in this trial and subsequent larger trials with more complex narrowings, bioabsorbable device technology may become the new standard of care for patients with coronary artery disease."

Abbott is the only company with long-term clinical data (out to two years) evaluating the safety and performance of a fully bioabsorbable drug eluting coronary stent. Abbott's bioabsorbable everolimus eluting coronary device is made of polylactic acid, a proven biocompatible material that is commonly used in medical implants such as absorbable sutures. As with a metallic stent, Abbott's bioabsorbable device is designed to restore blood flow by propping a clogged vessel open, and to provide support until the blood vessel heals. Unlike a metallic stent, however, a bioabsorbable device is designed to be slowly metabolized by the body and completely absorbed over time.

"Abbott has been on the front lines of innovation in stent technology, and the fully bioabsorbable device is on track to become a clinical reality for patients," said John M. Capek, Ph.D., executive vice president, Medical Devices, Abbott. "Abbott is the furthest ahead in its clinical programs to bring a bioabsorbable drug eluting device to patients, and the company is com
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
2. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
3. Abbott Receives Complete Response Letter From FDA for Controlled-Release Hydrocodone With Acetaminophen
4. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
5. Continuous Treatment With Abbotts HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
6. Abbotts Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
7. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
8. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
9. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
10. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Ill. , Sept. 22, 2014  AbbVie ... from several clinical studies evaluating potential new medicines ... at the upcoming 2014 European Society of Medical ... Madrid, Spain . Data being presented ... the safety and efficacy of veliparib (ABT-888), a ...
(Date:9/22/2014)... DIEGO , Sept. 22, 2014 Arena Pharmaceuticals, ... company is scheduled to present a corporate overview and ... on Friday, September 26, 2014, at 11:30 a.m. Eastern ... Hotel in New York City . ... will be available under the investor relations section of ...
(Date:9/22/2014)... According to the new ... (Equipment, Media and Reagents), by Source, by type, ... Toxicity Testing, Research, Drug Discovery) - Analysis & ... and studies the major market drivers, threats, opportunities, ... data tables and 64 figures spread through 225 ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4
(Date:9/22/2014)... A surprising new study pulls back the curtain on ... differences in payment and income between physicians who perform ... , Contrary to perception, the research indicates, the physician ... and other procedure-performing doctors. , The new findings counter ... pay per minute explains why doctors who perform procedures ...
(Date:9/22/2014)... Mozes HealthDay Reporter MONDAY, ... American parents are aware of online physician-rating sites, and more ... their children, according to a new national study. The ... -- further suggest that negative online ratings may dissuade parents ... recommended by a neighbor. Conversely, a positive online rating ...
(Date:9/22/2014)... South Asians living in Canada have a higher rate ... compared with while people, McMaster researchers have found. ... Canadian Medical Association Journal (CMAJ Open) and may ... the fastest-growing ethnic groups in the country is the ... Canada, comprising about three percent of the population. They ...
(Date:9/22/2014)... researchers have published a pilot study showing the ... people with multiple sclerosis (MS). Improvements were ... and pain. "Development and effectiveness of a ... Description and outcomes" was epublished ahead of print ... of MS Care (doi: 10.7224/1537-2073.2013-045). The authors ...
(Date:9/22/2014)... Two new prescription devices approved by the U.S. Food ... people with migraine headaches who don,t tolerate migraine medications ... -- the Cefaly -- is designed to prevent migraines, ... meant to be used when migraines first start, according ... looking for alternative migraine treatments. Because these devices aren,t ...
Breaking Medicine News(10 mins):Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 2Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 4Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 2Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 3Health News:Higher risk of heart disease for South Asians in Canada 2Health News:Noninvasive Devices May Help Migraines, FDA Says 2
... from several misconceptions that people had about aging. A popular ... the happiest days of people's lives occur when they're young ... ,While old age was equated with unhappiness for other people, ... their old age. In other words older people seem to ...
... it is evident that a man is very critical and is ... and is admitted// in a Shenzhen hospital. It is very evident ... SAR's Centre for Health Protection said that the victim lives in ... a Hong Konger residing in Shenzhen. He fell ill after he ...
... and figures seemingly indicate that the number of violent ... over the past year//. According to the figures that ... shows that the staff had reported 224 incidents of ... ,Unison an organization that represents the health workers, says ...
... Cancer researchers in UK exclaimed children now become fond of ... meat// and fish – after surveying about 200 pairs of ... strong in high-protein dishes such as beef, lamb, fish, bacon ... to taste vegetables and dessert more preferably. ,Mothers ...
... According to the study it was found that Implantable ... //. But they are very efficient in reducing the ... published in the American Heart Association rapid access journal ... were sicker and more prone to develop heart failure,’ ...
... seizures, or psychogenic seizures are often misdiagnosed as epileptic ... epilepsy is caused by the abnormal electrical activity in ... are similar to epileptic seizures, they can be difficult ... 13, 2006, issue of Neurology, the scientific journal of ...
Cached Medicine News:Health News:Attitudes About Aging Different from Reality 2Health News:Attitudes About Aging Different from Reality 3Health News:Violence Against NHS Staff On The Raise 2Health News:Defibrillators Can Only Put off Heart Failure but Cannot Prevent One 2Health News:Clues To Identify Psychological Seizures 2Health News:Clues To Identify Psychological Seizures 3
... Safety Knife with BD Xstar Blade includes ... protects the blade in prodedure and handling. ... on a grind-less process for manufacturing surgical ... sharpness and consistency. The arch style, ...
... Knife with BD Xstar Blade includes a ... the blade in prodedure and handling. ... a grind-less process for manufacturing surgical blades. ... and consistency. The arch style, single-bevel ...
... The BD Safety Knife with BD ... retractable shield that protects the blade in ... technology is based on a grind-less process ... process yields outstanding sharpness and consistency. ...
Bio-Rad's Genetic Systems HIV-1/HIV-2 PLUS O EIA is a unique assay that detects the broadest range of HIV....
Medicine Products: